To determine whether these effects were tumor‐specific, we also analyzed circulating CD8+ T cells in the blood and found no significant changes in CD8+ T cell frequency following DHB or BAPN treatment (Figure S5D, Supporting Information), indicating a localized effect within the tumor microenvironment. This evidence concerns the gene CD8A and neoplasm.